LOXO ONCOLOGY,INC. (NASDAQ:LOXO) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD.
On September27, 2017, Loxo Oncology,Inc. (“Loxo Oncology”) issued a press release announcing details of the LOXO-292 abstract to be presented by study investigators at the International Association for the Study of Lung Cancer 18thWorld Conference on Lung Cancer on October18, 2017 in Yokohama, Japan. A copy of the press release and the abstract are furnished as Exhibit99.1 and 99.2, respectively, to this report and incorporated herein by reference.
The information furnished with this report, including Exhibit99.1 and Exhibit99.2, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits.
Loxo Oncology, Inc. ExhibitEX-99.1 2 a17-22519_1ex99d1.htm EX-99.1 Exhibit 99.1 Loxo Oncology Announces Details of LOXO-292 Abstract to be Presented as Late-Breaking Presentation at the IASLC 18th World Conference on Lung Cancer STAMFORD,…To view the full exhibit click here
About LOXO ONCOLOGY,INC. (NASDAQ:LOXO)
Loxo Oncology, Inc. is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer. Its pipeline includes LOXO-101, LOXO-195, Rearranged During Transfection (RET) Program and Fibroblast Growth Factor Receptor (FGFR) program. LOXO-101 is a selective inhibitor of tropomyosin receptor kinases (TRK) for the treatment of patients with soft tissue sarcoma. LOXO-195 is a selective TRK inhibitor capable of addressing potential mechanisms of acquired resistance that may emerge in patients receiving LOXO-101 or multikinase inhibitors with anti-TRK activity. It has designed a series of RET inhibitors that optimize on-target potency for RET gene fusions, mutations and clinically-identified resistance mutations. It is designing FGFR1-sparing FGFR inhibitor.